title: Role of targeted agents in metastatic colorectal cancer.
abstract: Despite a decrease in incidence and mortality, colorectal cancer (CRC) still represents the second leading cause of cancer worldwide. Recurrence following surgery and adjuvant treatment and the metastatic disease are still a major problem with a median overall survival of approximately 24 months. Nevertheless, there has been an improvement in outcome due to the introduction into clinical practice of new cytotoxic and targeted agents. The targeted agents that have improved the efficacy of the available chemotherapeutic regimens in CRC are the ones that target the vascular endothelial growth factor (VEGF) and the epidermal growth factor receptor (EGFR). In particular, bevacizumab, a recombinant humanized monoclonal antibody against VEGF, cetuximab, and panitumumab, two monoclonal antibodies that target the EGFR, have been approved for the treatment of metastatic CRC (mCRC). While for anti-EGFR agents, predictive biomarkers have been found, no good biomarkers have been found yet for anti-VEGF agents. Aflibercept and regorafenib have recently also been approved in patients with mCRC. This article reviews in an extensive way the data of large randomized clinical trials for the use of anti-VEGF and anti-EGFR in CRC. Aim of this review is also to describe the current status of biomarkers discovery and highlight how to improve the therapeutic index of these targeted agents by selecting in advance the subgroup of patients who will benefit from these treatments.
authors: Digestive Oncology, University Hospitals Leuven and KULeuven, Leuven, Belgium. hans.prenen@uzleuven.be
authors: Hans
authors: H
authors: Prenen
authors: Loredana
authors: L
authors: Vecchione
authors: Eric
authors: E
authors: Van Cutsem
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D017326:Clinical Trials, Phase III as Topic; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000378:metabolism* / Q000473:pathology; D006801:Humans; D058990:Molecular Targeted Therapy / Q000379:methods*; D009362:Neoplasm Metastasis; D057285:Precision Medicine / Q000379:methods; D016032:Randomized Controlled Trials as Topic
references: Nature. 2012 Jun 28;486(7404):532-6
references: 22722830
references: Sci Transl Med. 2011 Sep 7;3(99):99ra86
references: 21900593
references: J Clin Oncol. 2011 Jul 1;29(19):2675-82
references: 21646616
references: Proc Natl Acad Sci U S A. 2002 Feb 5;99(3):1521-6
references: 11818567
references: CA Cancer J Clin. 2011 Jul-Aug;61(4):212-36
references: 21685461
references: Br J Cancer. 2009 Aug 4;101(3):465-72
references: 19603024
references: Int J Cancer. 2007 Feb 15;120(4):781-7
references: 17096332
references: J Clin Oncol. 2010 Nov 1;28(31):4706-13
references: 20921462
references: Ann Oncol. 2010 Jun;21(6):1152-1162
references: 19942597
references: J Clin Oncol. 2008 Dec 10;26(35):5705-12
references: 19001320
references: Ann Oncol. 2008 Apr;19(4):717-23
references: 17974556
references: Cancer Discov. 2011 Nov;1(6):508-23
references: 22586653
references: Nat Rev Cancer. 2008 Aug;8(8):579-91
references: 18596824
references: Nature. 2009 May 14;459(7244):262-5
references: 19329995
references: Exp Cell Res. 2009 Feb 15;315(4):583-601
references: 19041864
references: N Engl J Med. 2004 Jun 3;350(23):2335-42
references: 15175435
references: Lancet Oncol. 2010 Aug;11(8):753-62
references: 20619739
references: N Engl J Med. 2008 Oct 23;359(17):1757-65
references: 18946061
references: J Clin Oncol. 2004 Apr 1;22(7):1209-14
references: 15051767
references: J Clin Oncol. 2007 Apr 20;25(12):1539-44
references: 17442997
references: J Clin Oncol. 2004 Apr 1;22(7):1201-8
references: 14993230
references: Clin Cancer Res. 2009 May 1;15(9):3184-8
references: 19366826
references: Cancer Res. 2009 Mar 1;69(5):1851-7
references: 19223544
references: Lancet Oncol. 2012 Oct;13(10):e427-36
references: 23026828
references: Oncologist. 2012;17(8):1039-50
references: 22773560
references: Ann Oncol. 2012 Oct;23(10):2479-2516
references: 23012255
references: Cancer Res. 2001 Jul 1;61(13):5090-101
references: 11431346
references: Oncology. 2010;78(5-6):376-81
references: 20798560
references: Nature. 2012 Jun 28;486(7404):537-40
references: 22722843
references: J Clin Oncol. 2008 May 10;26(14):2311-9
references: 18390971
references: Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37
references: 11252954
references: J Clin Oncol. 2008 Apr 1;26(10):1626-34
references: 18316791
references: Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):984-90
references: 14967460
references: Lancet Oncol. 2007 May;8(5):387-94
references: 17466895
references: N Engl J Med. 2007 Nov 15;357(20):2040-8
references: 18003960
references: Lancet. 2013 Jan 26;381(9863):303-12
references: 23177514
references: J Clin Oncol. 2004 Jan 15;22(2):229-37
references: 14657227
references: N Engl J Med. 2008 Mar 13;358(11):1160-74
references: 18337605
references: Nature. 2012 Jan 26;483(7387):100-3
references: 22281684
references: Eur J Cancer. 2013 Apr;49(6):1161-8
references: 23265711
references: J Clin Oncol. 2009 Dec 10;27(35):5924-30
references: 19884556
references: Cancer Res. 2006 Apr 15;66(8):3992-5
references: 16618717
references: Crit Rev Oncol Hematol. 2001 Apr;38(1):17-23
references: 11255078
references: Nat Med. 2012 Jan 22;18(2):221-3
references: 22270724
references: J Clin Oncol. 2012 May 20;30(15):1755-62
references: 22473155
references: N Engl J Med. 2004 Dec 30;351(27):2883
references: 15625347
references: Lancet Oncol. 2012 Jul;13(7):724-33
references: 22608783
references: J Clin Oncol. 2009 Feb 10;27(5):672-80
references: 19114685
references: Am J Clin Oncol. 2011 Dec;34(6):573-80
references: 21217399
references: J Clin Oncol. 2001 Feb 1;19(3):843-50
references: 11157038
references: N Engl J Med. 2011 Jun 30;364(26):2507-16
references: 21639808
references: Cancer. 2009 Oct 15;115(20):4849-56
references: 19626652
references: Cancer Res. 2012 Nov 15;72(22):5801-11
references: 22986738
references: Lancet. 2011 Jun 18;377(9783):2103-14
references: 21641636
references: Expert Opin Investig Drugs. 2012 Jun;21(6):879-89
references: 22577890
references: Br J Cancer. 2001 Sep 1;85(5):692-6
references: 11531254
references: Target Oncol. 2011 Dec;6(4):227-33
references: 22113391
references: Clin Cancer Res. 2008 Sep 15;14(18):5869-76
references: 18794099
references: J Clin Oncol. 2009 Oct 20;27(30):5068-74
references: 19738126
references: J Clin Oncol. 2007 May 1;25(13):1658-64
references: 17470858
references: BMC Cancer. 2009 Sep 28;9:347
references: 19785749
references: J Clin Oncol. 2008 Oct 10;26(29):4828-33
references: 18711170
references: J Clin Oncol. 2009 Apr 20;27(12):2091-6
references: 19188670
references: Med Oncol. 2009;26(1):32-7
references: 18498064
references: J Clin Oncol. 2007 Aug 1;25(22):3230-7
references: 17664471
references: Expert Opin Biol Ther. 2009 Feb;9(2):263-71
references: 19236257
references: Br J Cancer. 2007 Apr 23;96(8):1166-9
references: 17375050
references: J Clin Oncol. 2005 Aug 1;23(22):4866-75
references: 15939922
references: J Clin Oncol. 2011 May 20;29(15):2011-9
references: 21502544
references: N Engl J Med. 2005 Jul 14;353(2):208-9
references: 16014894
references: J Clin Oncol. 2007 Aug 1;25(22):3238-45
references: 17664472
references: N Engl J Med. 2009 Apr 2;360(14):1408-17
references: 19339720
references: J Clin Oncol. 2012 Oct 1;30(28):3499-506
references: 22949147
references: Oncol Rep. 2009 Apr;21(4):1023-8
references: 19288004
references: J Clin Oncol. 2010 Jan 20;28(3):453-9
references: 20008624
references: Eur J Cancer. 2001 Sep;37 Suppl 4:S3-8
references: 11597398
references: Onco Targets Ther. 2013;6:53-8
references: 23378775
references: Nature. 2011 Jan 20;469(7330):415-8
references: 21113151
references: J Clin Oncol. 2012 Aug 10;30(23):2861-8
references: 22753904
references: JAMA. 2010 Oct 27;304(16):1812-20
references: 20978259
references: Cancer Epidemiol Biomarkers Prev. 2000 Nov;9(11):1193-7
references: 11097226
references: Ann Oncol. 2008 Mar;19(3):508-15
references: 17998284
references: Ann Oncol. 2009 Nov;20(11):1842-7
references: 19406901
references: Nature. 2012 Jul 26;487(7408):505-9
references: 22763448
references: PLoS One. 2011 Jan 20;6(1):e15980
references: 21283802
references: J Clin Oncol. 2008 Jan 20;26(3):374-9
references: 18202412
references: Lancet Oncol. 2005 May;6(5):279-86
references: 15863375
references: Cancer Sci. 2007 Aug;98(8):1275-80
references: 17498200
references: N Engl J Med. 2004 Jul 22;351(4):337-45
references: 15269313
references: Ann Oncol. 2009 Jan;20(1):84-90
references: 18669866
references: Lancet Oncol. 2013 Jan;14(1):29-37
references: 23168366
references: Nat Med. 2001 May;7(5):575-83
references: 11329059
references: J Clin Oncol. 2005 Mar 20;23(9):1803-10
references: 15677699
references: J Clin Oncol. 2009 Feb 10;27(5):663-71
references: 19114683
references: J Clin Oncol. 2010 Nov 1;28(31):4697-705
references: 20921465
references: Am J Physiol. 1999 Sep;277(3):G533-40
references: 10484377
references: Nat Rev Clin Oncol. 2009 Jun;6(6):327-38
references: 19483739
references: J Clin Oncol. 2010 Mar 1;28(7):1181-9
references: 20100964
references: J Clin Oncol. 2008 Feb 1;26(4):689-90
references: 18235136
references: J Clin Oncol. 2006 Jul 20;24(21):3354-60
references: 16849749
references: N Engl J Med. 2009 Feb 5;360(6):563-72
references: 19196673
references: Science. 2007 Nov 16;318(5853):1108-13
references: 17932254
references: J Clin Oncol. 2008 Apr 20;26(12):2013-9
references: 18421054
references: Clin Cancer Res. 2009 Mar 15;15(6):1860-4
references: 19240167
references: Br J Cancer. 2009 Aug 18;101(4):715-21
references: 19603018
references: J Clin Oncol. 2012 Oct 10;30(29):3570-7
references: 22734028